Loading...
Please wait, while we are loading the content...
Similar Documents
Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study
| Content Provider | Scilit |
|---|---|
| Author | Cheng, Shih-Lung Ho, Ming-Lin Lai, Yun-Fa Wang, Hao-Chien Hsu, Jeng-Yuan Liu, Shih-Feng Huang, Ming-Shyang Lee, Cheng-Hung Lin, Ching-Hsiung Hang, Liang-Wen Liu, Yu-Chih Yang, Kuang-Yao Wang, Jia-Horng |
| Copyright Year | 2020 |
| Description | Journal: Drug design, development and therapy |
| Abstract | Introduction: In the prospective, observational, 16-week REACT study conducted between October 21, 2008 and May 12, 2011, we compared the real-world effectiveness of anti-inflammatory reliever and maintenance therapy with budesonide/formoterol $(Symbicort^{®}$ Turbuhaler) and maintenance therapy with fixed-dose fluticasone/salmeterol $(Seretide^{®}$) plus as-needed, short-acting $β_{2}$ agonists (SABAs) in Taiwanese patients with inadequate asthma control. Methods: Asthma control was assessed using the five-item Asthma Control Questionnaire (ACQ-5) and standardized pulmonary function testing. Assessments were performed at baseline and at weeks 4– 5 and 12– 16. Overall, we enrolled 842 patients at 11 clinics, 723 of whom were included in analyses (budesonide/formoterol, 563.3± 1.3 μg/d, n=551; fluticasone/salmeterol, 1013.8± 1.4 μg/d, n=172). Results: At baseline, 72.5% and 27.5% of all patients had “partly” and “uncontrolled” asthma, respectively. Mean±SD ACQ-5 scores were 1.54± 1.06 and 1.46± 1.28 in the budesonide/formoterol and fluticasone/salmeterol groups, respectively. ACQ-5 scores significantly improved from baseline (ie, decreased) in both groups at weeks 4 and 16. ACQ-5 difference scores were significantly lower in the budesonide/formoterol group (− 0.91± 1.11) than the fluticasone/salmeterol group (− 0.69± 1.27) at the end of the study (p=0.027). Peak expiratory flow rate significantly improved from baseline in the budesonide/formoterol but not the fluticasone/salmeterol group at the end of the study. Severe exacerbation rates and medical resource utilization were comparable between the budesonide/formoterol and fluticasone/salmeterol groups. Conclusion: Collectively, results indicate the real-world effectiveness of budesonide/formoterol anti-inflammatory reliever and maintenance therapy is better than fixed-dose fluticasone/salmeterol plus as-needed SABA. Trial Registration: ClinicalTrials.gov registration number: NCT00784953. |
| Related Links | https://www.dovepress.com/getfile.php?fileID=64547 |
| Ending Page | 5450 |
| Page Count | 10 |
| Starting Page | 5441 |
| e-ISSN | 11778881 |
| DOI | 10.2147/dddt.s266177 |
| Journal | Drug design, development and therapy |
| Volume Number | ume 14 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2020-12-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Drug design, development and therapy Respiratory System Budesonide/formoterol Fluticasone Propionate/salmeterol Anti-inflammatory Reliever and Maintenance |
| Content Type | Text |
